Stem cell therapies for TM regeneration provide a robust and promising suite of treatments for eventual lowering of IOP and prevention of glaucomatous vision loss in humans in the future. Further investigation into stem cell homing mechanisms and the safety of introducing these cells into human anterior chamber, for instance, are required before clinical applications in treating glaucoma patients.
Keyphrases
- stem cells
- end stage renal disease
- endothelial cells
- chronic kidney disease
- optic nerve
- induced apoptosis
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- cell therapy
- bone mineral density
- cell cycle arrest
- current status
- cell proliferation
- signaling pathway
- patient reported outcomes
- risk assessment
- induced pluripotent stem cells
- body composition
- postmenopausal women
- pluripotent stem cells